Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.32 |
| ▸ | GSR | P00390 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5856024 | 0.92 | TBXAS1 (0.36) | ENPEPTSHRLMNAALDH1A1TDP1 | |
| SCHEMBL6474908 | 0.89 | TBXAS1 (0.39) | ENPEPTSHRLMNAALDH1A1TBXAS1 | |
| SCHEMBL5855808 | 0.89 | TBXAS1 (0.39) | ENPEPTSHRLMNAALDH1A1TBXAS1 | |
| SCHEMBL10576164 | 0.85 | CA2 (0.32) | TDP1CA2MAPK1CHRM1AKR1A1 | |
| SCHEMBL9705800 | 0.81 | ENPEP (0.40) | ENPEPTSHRLMNAALDH1A1TDP1 | |
| SCHEMBL9308206 | 0.81 | ENPEP (0.43) | ENPEPALDH1A1TDP1TBXAS1GSR | |
| SCHEMBL12851496 | 0.81 | GSR (0.43) | ENPEPTDP1TBXAS1GSRCA2 | |
| SCHEMBL7753637 | 0.78 | — | — | |
| SCHEMBL28733920 | 0.78 | — | — | |
| SCHEMBL1706453 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1533322-B1 | SOLID CATALYST COMPONENT FOR OLEFIN POLYMERIZATION AND CATALYST | TOHO TITANIUM CO LTD (JP) | 2019-05-01 | — | — | EP | disclosed |
| EP-2658855-A2 | NOVEL POLYKETIDE COMPOUNDS AND METHODS OF MAKING SAME | Acies Bio d.o.o. (SI) | 2013-11-06 | — | — | EP | disclosed |
| WO-2012089349-A2 | NOVEL POLYKETIDE COMPOUNDS AND METHODS OF MAKING SAME | ACIES BIO D.O.O. (SI) | 2012-07-05 | — | — | WO | disclosed |
| US-20090118314-A1 | TUMOR SUPPRESSOR | JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF AGENCY CENTER (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-2022500-A1 | TUMOR SUPPRESSOR | JAPAN as represented by DIRECTOR GENERAL OF AGENCY OF NACIONAL CANCER CENTER (JP) | 2009-02-11 | — | — | EP | disclosed |
| US-7208435-B2 | Solid catalyst component for olefin polymerization and catalyst | TOHO CATALYST CO., LTD. (JP) | 2007-04-24 | — | — | US | disclosed |
| US-7144906-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-12-05 | — | — | US | disclosed |
| US-7030143-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-7022723-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1634876-A2 | Heterocyclic compounds for the treatment of hyperlipidemia agents | Nippon Shinyaku Co., Ltd. (JP) | 2006-03-15 | — | — | EP | disclosed |
| EP-0929519-B1 | BETA-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | UPJOHN CO (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20050009892-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20050009785-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040162325-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2004-08-19 | — | — | US | disclosed |
| US-20030166697-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1295875-A1 | HETEROCYCLIC COMPOUNDS | Nippon Shinyaku Co., Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
| US-6235928-B1 | ENZYME INHIBITOR MATRIX METALLOPROTEINASE FAMILY, INCLUDING COLLAGENASE, STROMELYSIN, AND GELATINASE, THE COMPOUNDS OR PHARMACEUTICAL COMPOSITIONS | PHARMACIA & UPJOHN COMPANY | 2001-05-22 | — | — | US | disclosed |
| EP-0929519-A1 | $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-21 | — | — | EP | disclosed |
| US-5847153-A | β-sulfonyl hydroxamic acids | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-08 | — | — | US | disclosed |
| WO-1998013340-A1 | β-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009785-A1 | Heterocyclic compounds | LIPC, GPR119, APOB | ENPEP 1911/4885TSHR 1666/4885LMNA 606/4885 |
| US-20050009892-A1 | Heterocyclic compounds | GPR119, LIPC, LIPE | ENPEP 2177/4885TSHR 2487/4885LMNA 601/4885 |
| US-20090118314-A1 | TUMOR SUPPRESSOR | VHL, APC, SRRT | ENPEP 3635/4885TSHR 3055/4885LMNA 2856/4885 |
| US-20040162325-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | ENPEP 1844/4885TSHR 2672/4885LMNA 636/4885 |
| US-20030166697-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | ENPEP 1844/4885TSHR 2672/4885LMNA 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.